EVT-101, also known as ENS-101, is an experimental medication which originated from Roche and is under development by Evotec AG for the treatment of major depressive disorder.[1] It acts as a selective NMDA receptor subunit 2B (NR2B) antagonist.[1][2] The drug was first claimed by Roche in 2002.[3] By 2017, EVT-101 was in phase II clinical trials for major depressive disorder; however, development of the drug was discontinued in 2021.[1]
Clinical data | |
---|---|
Other names | ENS-101 |
Drug class | NMDA receptor antagonist |
Identifiers | |
| |
CAS Number |
|
PubChem CID | |
ChemSpider | |
UNII | |
ChEMBL | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C16H13F3N4 |
Molar mass | 318.303 g·mol−1 |
3D model (JSmol) | |
| |
|
See also
editReferences
edit- ^ a b c "EVT 101 - AdisInsight".
- ^ "Archived copy" (PDF). Archived from the original (PDF) on 2017-08-29. Retrieved 2018-02-10.
{{cite web}}
: CS1 maint: archived copy as title (link) - ^ Santangelo RM, Acker TM, Zimmerman SS, Katzman BM, Strong KL, Traynelis SF, Liotta DC (2012). "Novel NMDA receptor modulators: an update". Expert Opin Ther Pat. 22 (11): 1337–52. doi:10.1517/13543776.2012.728587. PMC 3677696. PMID 23009122.